Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$36.87 USD
-0.93 (-2.46%)
Updated May 20, 2024 04:00 PM ET
After-Market: $36.84 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SYRE 36.87 -0.93(-2.46%)
Will SYRE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Positive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial Stability
Buy Rating Affirmed on Spyre Therapeutics as SPY001 Shows Promise Over Market Leader
Buy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive Outlook